Dosy
FAQSupport

The Best GLP-1 Tracking App in 2026

Most health apps treat GLP-1 medications as an afterthought. Dosy Health was built from day one specifically for people on Ozempic®, Wegovy®, Mounjaro®, Zepbound®, Foundayo®, and compounded GLP-1 medications. Here's what makes it different.

The problem

What GLP-1 Users Actually Need from an App

General fitness apps and basic medication reminders don't address the specific challenges of GLP-1 therapy:

Medication-specific tracking, not generic pill reminders
GLP-1 therapy involves injection timing, site rotation, dose titration, and for compounded users — concentration math. A generic 'did you take your pill?' notification doesn't cover this.
Pharmacokinetic awareness
GLP-1 medications have long half-lives (5-7 days for weekly injectables). Understanding estimated levels between doses helps you contextualize appetite changes and side effects throughout the week.
Weight loss + nutrition in one place
GLP-1 users are tracking weight, adjusting calories as appetite decreases, and monitoring macros. Having medication data alongside nutrition eliminates switching between multiple apps.
Compounded medication support
Millions of users are on compounded GLP-1 from pharmacies — they need dose calculators, custom concentrations, and vial inventory tracking that branded-pen-only apps don't offer.
Doctor-ready data
Your provider needs to see your injection history, weight trend, and side effects at each visit. An app should produce this report in one tap, not make you summarize from memory.
Dosy Health

Everything in One App

Your All-in-One GLP-1 Tracker
Smart Injection Rotation & Nutrition
Every Meal. Every Macro.
Your Complete GLP-1 Journey
Personalized For Your Goals
More Than Just A Tracker
Built by GLP-1 Users
Your Journey Starts Here
7 GLP-1 molecules supported
Estimated medication levels
Smart injection site rotation
Built-in dose calculator
Vial inventory tracking
Weight trend charts
Meal tracking (2M+ foods)
Smart macro targets
Daily health dashboard
PDF reports for providers
Apple Health & Health Connect
Smart reminders
Medication support

Every Major GLP-1 Medication

Dosy supports branded pens, compounded vials, and oral formulations — with medication-specific pharmacokinetic modeling for each:

MoleculeBrand(s)Type
SemaglutideOzempic®, Wegovy®Weekly injection
TirzepatideMounjaro®, Zepbound®Weekly injection
LiraglutideSaxenda®, Victoza®Daily injection
DulaglutideTrulicity®Weekly injection
Retatrutide(investigational)Weekly injection
OrforglipronFoundayo®Daily oral
Semaglutide (oral)Rybelsus®Daily oral

Free Core, Optional Premium

Core tracking is free forever — injection logging, weight tracking, dose calculator, smart rotation, reminders, and Apple Health sync. Dosy+ ($19.99/year) adds estimated medication levels, AI insights, advanced meal tracking (photo/voice/barcode), and PDF reports.

Medical Disclaimer

Dosy Health is an educational and tracking tool only. It does not provide medical advice, diagnosis, or treatment recommendations. All dosing decisions must be made by your healthcare provider.

Do not rely on any app, including Dosy, as a substitute for professional medical guidance. Always confirm your dose and injection instructions with your prescribing provider and pharmacist.

Dosy Health is not affiliated with, endorsed by, or associated with Novo Nordisk (manufacturer of Ozempic®, Wegovy®, Saxenda®, and Victoza®), Eli Lilly (manufacturer of Mounjaro®, Zepbound®, Trulicity®, and Foundayo®), or any compounding pharmacy.

Try Dosy Free

The GLP-1 tracking app built by people who understand the medication.

Download on the App Store
Get it on Google PlaySoon

Sources

  1. Marbury TC, et al. "Pharmacokinetics and Tolerability of a Single Dose of Semaglutide." Clinical Pharmacology in Drug Development, 2017. — semaglutide half-life ~7 days.
  2. Coskun T, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist." Molecular Metabolism, 2018. — tirzepatide dual-receptor mechanism and ~5 day half-life.
  3. Novo Nordisk. Ozempic® (semaglutide) and Wegovy® (semaglutide) Prescribing Information. Revised 2024.
  4. Eli Lilly. Mounjaro® (tirzepatide) and Zepbound® (tirzepatide) Prescribing Information. 2023–2024.
  5. Eli Lilly. Foundayo® (orforglipron) Prescribing Information. 2026.
  6. U.S. Food & Drug Administration. "Compounding and the FDA: Questions and Answers." FDA.gov